D Wave Quantum Inc vs BIO-TECHNE Corp — how do they compare? D Wave Quantum Inc trades at $17.33 (market cap $6.59B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| QBTS | TECH | |
|---|---|---|
Market Cap | $6.59B | $11.16B |
Sector | Technology | Health |
52-Week High | $44.78 | $72.12 |
52-Week Low | $12.98 | $43.31 |
Enterprise Value | $6.05B | $11.24B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $16.73, showing no change in the last 24 hours. The stock is technically bearish with key support at $16 and resistance at $17. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent news highlights D-Wave's dual-platform quantum computing approach and a recent transfer of its stock listing to Nasdaq (Business Wire, July 14, 2026).
Despite unanimous analyst buy ratings and a $39.86 consensus price target implying significant upside, QBTS faces substantial execution risks. High cash burn, negative profitability, and intense competition in the emerging quantum computing sector present challenges. The stock's appeal hinges on future revenue growth materializing from current commercial partnerships and technological advancements.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Trailing returns across standard periods
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →